Is endocrine surveillance important in the care of Duchenne Muscular Dystrophy? Results from a national survey to patients and families on endocrine complications

• Published in: eNeurologicalSci 2024-09, Vol.36, p.100513, Article 100513
• Main Authors: Galetaki, Despoina, Szymczuk, Vivian, Shi, Melody, Merchant, Nadia
• Format: Article
• Language: English
• Subjects: Adrenal insufficiency; Duchenne muscular dystrophy; Endocrine; Growth; Obesity; Original; Puberty; Steroids
• ISSN: 2405-6502; 2405-6502
• DOI: 10.1016/j.ensci.2024.100513

Glucocorticoids are standard of care for patients with Duchenne muscular dystrophy (DMD). Although prolonged exposure is associated with multiple endocrine side effects, current guidelines related to monitoring and management of endocrinopathies are suboptimal. We aim to explore community perceptions of endocrine related complications in patients with DMD, assess current level of understanding, and desire for further education. A 31-item online survey was sent through Parent Project to Muscular Dystrophy (PPMD) to Duchenne Registry members to be completed by patients or their caretakers. Response rate was 55% (n = 75). Steroids were taken by 93%, but only 50% were followed by endocrinology and 21% report never been seen by endocrinology. Bone health was discussed with 87% of patients and 60% were diagnosed with osteoporosis. Delayed puberty was discussed with 41% of patients with 23% receiving testosterone therapy. About half the patients reported a diagnosis of slowed growth. Only 51% of the participants recalled discussing adrenal insufficiency. Obesity was discussed with 59% of participants. Families felt education about steroid-induced endocrinopathies to be very or extremely important and prefer to discuss about this at the beginning of their steroid therapy. This demonstrates significant gaps in education and access to endocrine care in patients with DMD. [Display omitted] •Current approach to steroid induced endocrinopathies does not meet the needs of the DMD community.•Patients want to be informed early about endocrine complications of steroids.•Important to include endocrinology in DMD team and endocrine complications in clincal trials.